Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab
- 19 April 2015
- journal article
- case report
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 173 (1), 239-241
- https://doi.org/10.1111/bjd.13614
Abstract
Generalized pustular psoriasis (GPP) is a severe, potentially life-threatening inflammatory dermatosis, which is traditionally difficult to manage. Recent evidence suggests that interleukin (IL)-1 plays a central role in the disease pathogenesis, and thus makes the use of IL-1 inhibitors potentially effective. Two patients with severe, recalcitrant GPP were enrolled in an open-label, expanded access study to receive a new IL-1β inhibitor, gevokizumab. The two patients had a respective 79% and 65% reduction in GPP area and severity index scores at weeks 4 and 12, with some improvements in quality-of-life instruments. There were no significant adverse events related to the study medication, although one patient developed an abscess in a haematoma secondary to an injury. Both patients showed substantial initial clinical response to gevokizumab, with no significant laboratory abnormalities noted. These cases illustrate the growing need for targeted, efficacious therapies for this severe, debilitating disease. Prospective randomized control studies are required to further assess the safety and efficacy of IL-1β inhibitors for the treatment of GPP.This publication has 10 references indexed in Scilit:
- Partial clinical response to anakinra in severe palmoplantar pustular psoriasisBritish Journal of Dermatology, 2014
- The Majority of Generalized Pustular Psoriasis without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor AntagonistJournal of Investigative Dermatology, 2013
- First Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With AnakinraPEDIATRICS, 2013
- Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular PsoriasisArchives of Dermatology, 2012
- Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis FoundationJournal of the American Academy of Dermatology, 2012
- Interleukin 1 Receptor Antagonist Deficiency Presenting as Infantile Pustulosis Mimicking Infantile Pustular PsoriasisArchives of Dermatology, 2012
- Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular PsoriasisThe New England Journal of Medicine, 2011
- Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN MutationsAnnals of Internal Medicine, 2010
- Palmoplantar psoriasis: A phenotypical and clinical review with introduction of a new quality-of-life assessment toolJournal of the American Academy of Dermatology, 2009
- An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor AntagonistThe New England Journal of Medicine, 2009